NextBio

Help
Description: Quinapril is used in the treatment of hypertension and congestive heart failure. Quinapril is actually a prodrug. It is converted to its active metabolite, quinaprilat, in the liver. Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Quinapril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension and heart failure. Like ramipril, quinapril is a prodrug that, upon deesterification, is converted to the active metabolite quinaprilat. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation.
Mechanism of Action: Quinaprilat competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms. Quinaprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Indication: For the treatment of hypertension and chronic heart failure.
Half Life: 2 hours
View Complete Description



Data Correlations | 1 study

Help for Data Correlations View All
Genes category icon Genes
Score Help
ACE 100 100
View Top Genes
Biogroups category icon Biogroups
Score Help
ACE Inhibitor Pathway 100 100
Renin Angiotensin System 97 97
Peptidase M, neutral zinc metallope… 93 93
MMP Cytokine Connection 91 91
View Top Biogroups

Individual Studies

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Quinapril.

View All Author iconAuthors
  • Wiek H van Gilst
  • Orhan Onalan
  • George Zografi
  • Sidney Chocron
  • Cristina-Dana Calciu
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Pfizer
  • Mylan Pharmaceuticals
  • University of Vigo
  • Montreal Heart Institute
  • Ranbaxy Laboratories Limited
View All Affiliations icon Organizations
  • University Medical Center Groningen
  • University of Wales
  • Montreal Heart Institute
  • Emory University School of Medicine
  • Baker IDI Heart and Diabetes Institute

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Quinapril”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “Quinapril”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio